Naslov
Pentadecapeptide BPC 157 therapy in rats with cysteamine induced-terminal ileitis

Autori
Samara, Mariam ; Radić, Božo ; Žižek, Helena ; Gojković, Slaven ; Krezić, Ivan ; Malekinušić, Dominik ; Đurašin, Tajana ; Drmić, Domagoj ; Amić, Fedor ; Petrović, Andrea ; Horvat, Katarina ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 158 (2020), 6(S) / - , 2020, S-503

Skup
Digestive Disease Week

Mjesto i datum
Online; konferencija, 02.05.2020. - 05.05.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
BPC 157 ; cysteamine ; colitis

Sažetak
Aim. In rats with 2 months of protracted terminal ileitis, induced by one single local application of the ulcerogenic cysteamine, we introduce pentadecapeptide BPC 157 as 1 month successful therapy. We counteracted gross hyperemia, edema, erosion, bleeding, and, microscopically, significant loss of villous architecture, loss and shortening of villae and severe lymphocytic infiltrate. BPC 157 counteracts various lesions in the whole GI-tract and free radicals formation (Curr Pharm Des 2018 ; 24:1990-2001), and tested in ulcerative colitis trials and now in multiple sclerosis (Curr Pharm Des 2018 ; 24:1990- 2001). Previously, cysteamine, was known to induce gastric acid hypersecretion, as a prototype of duodenal lesion (Lancet 1979 Oct 27 ; 2(8148):880-2). Subsequently, cysteamine induced duodenal lesions after gastrectomy, and applied as an enema, ulcerative colitis in rats. BPC 157 counteracts all of these lesions (Life Sci 1994 ; 54(5):PL63-8, Dig Dis Sci 1997 May ; 42(5):1029-37, J Physiol Paris 2001 Jan-Dec ; 95(1-6):283-8, J Physiol Paris 2001 Jan- Dec ; 95(1-6):261-70, Eur J Pharmacol 2003 Sep 5 ; 477(1):73-80, J Physiol Pharmacol 2013 Oct ; 64(5):597-612) Methods. Cysteamine (400 mg/kg, 1 ml/rat) was applied in female Albino Wistar rats, 200 g bw into the terminal ileum, 5 cm segment up to ileocecal valve, which was kept gently compressed for 1 min, and then released. Medication (/kg) (BPC 157 (10 µg, 10 ng), or saline (5 ml) (controls)) was applied, perorally in drinking water (0.16 µg/ml, 0.16 ng/ml, 12 ml/rat/day), either since beginning continuously (co-treatment regimen), or since 2 months (delayed regimen), till the end of 3 months period. Results. For gross assessment, the hyperemia, edema, erosion and bleeding scores (0-3) were summarized (giving the total 0-12 scoring, and assessed as Min/Med/Max). Control rats exhibit 8/8/9 at 2 months, and worsening at 3 months 11/11/ 12. Contrarily, all BPC 157 rats present markedly lower scoring 0/1/1 (co-treatment), 3/3/ 4 (delayed-regimen), 10 µg and 10 ng regimens Min/Med/Max, P<0.05, vs. control, at least. Microscopically, much like in patients, cysteamine induced terminal ileitis goes with submucosal congestion, significant loss of villous architecture, loss and shortening of villae, lamina propria infiltrated with mild to severe lymphocytic infiltrate much like intraepithelial lymphocytes infiltration and some epithelial elevation from lamina propria. Contrarily, better preservation of mucosal architecture appears in pentadecapeptide BPC 157 treated rats. There is only mild villous edema with capillary congestion and mild lymphocytic infiltrate.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA